Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Stomach Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumors 1Sarcoma 1Neoplasms 1Melanoma 1Liposarcoma 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1

Interventions

pembrolizumab 59Nivolumab 34Cyclophosphamide 21fludarabine 15Paclitaxel 12Ipilimumab 12atezolizumab 11Specimen Handling 11Magnetic Resonance Spectroscopy 10Carboplatin 10Docetaxel 9Cisplatin 9Gemcitabine 8Biopsy 8durvalumab 7aldesleukin 7Radiosurgery 7Interleukin-2 7Bevacizumab 7cemiplimab 6Pemetrexed 6fludarabine phosphate 5avelumab 5Radiotherapy 5Drug Therapy 5spartalizumab 4epacadostat 4enzalutamide 4Taxes 4Sirolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Famotidine × Gastrointestinal × Clear all
NCT00451880 2011-10-13

Study of XL281 in Adults With Solid Tumors

Exelixis

Phase 1 Completed
180 enrolled
DermatologicEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡